secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zoetis Inc. (ZTS)
CIK:        0001555280
Form:       8-K
Filed at:   2021-10-18T23:59:59+00:00
Accession:  0001193125-21-301194
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zoetis R&D chief Catherine Knupp to retire; Robert Polzer named successor effective Jan 1, 2022
--------------------------------------------------------------------------------

- Dr. Catherine Knupp will retire as EVP & President of R&D effective Dec 31, 2021.
- Robert J. Polzer, current SVP of Global Therapeutics, appointed EVP & President of R&D effective Jan 1, 2022.
- Polzer will report to CEO Kristin Peck and join the Zoetis Executive team.
- Knupp will remain as advisor through Feb 28, 2022 to assist with transition.
- Zoetis highlights over 1,100 new product introductions in the past five years under Knupp's leadership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555280/000119312521301194/0001193125-21-301194-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555280/000119312521301194/d467864d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-301194

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer